{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:45:38Z","timestamp":1745469938882,"version":"3.40.4"},"reference-count":7,"publisher":"S. Karger AG","issue":"3-4","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2009]]},"abstract":"<jats:p>&lt;i&gt;Aim:&lt;\/i&gt; It was the aim of this study to test the hypothesis that the voltage-gated sodium channel gene &lt;i&gt;SCN2A&lt;\/i&gt; R19K polymorphism confers liability to oxaliplatin-induced peripheral neuropathy (OXLIPN). &lt;i&gt;Methods:&lt;\/i&gt; Sixty-two patients with advanced colorectal cancer were genotyped, using allele-specific primers and SYBR green in real-time polymerase chain reaction. All patients had received adjuvant oxalipla-tin-based chemotherapy. The severity of OXLIPN was defined by means of the clinical total neuropathy score. Following the discontinuation of treatment, 36\/62 patients (58.1%) developed OXLIPN. Grade I neurotoxicity was revealed in 14 (38.9%) patients and grade II neurotoxicity in 22 (61.1%) patients. &lt;i&gt;Results:&lt;\/i&gt; From patients without OXLIPN (n = 26), 80.8% (n = 21) were homozygous for G, 19.2% (n = 5) were heterozygous (AG) and none was homozygous for A. The corresponding percentages for patients developing any grade of OXLIPN (n = 36) were similar. Likewise, among patients experiencing OXLIPN, insignificant differences in R19K genotypes were revealed between those with grade I versus grade II neurotoxicity. &lt;i&gt;Conclusion:&lt;\/i&gt; Our study failed to provide evidence to support a causal relationship between the &lt;i&gt;SCN2A&lt;\/i&gt; R19K polymorphism and OXLIPN.<\/jats:p>","DOI":"10.1159\/000236049","type":"journal-article","created":{"date-parts":[[2009,9,4]],"date-time":"2009-09-04T13:04:16Z","timestamp":1252069456000},"page":"254-256","source":"Crossref","is-referenced-by-count":11,"title":["Liability of the Voltage-Gated Sodium Channel Gene &lt;i&gt;SCN2A&lt;\/i&gt; R19K Polymorphism to Oxaliplatin-Induced Peripheral Neuropathy"],"prefix":"10.1159","volume":"77","author":[{"given":"Andreas A.","family":"Argyriou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna G.","family":"Antonacopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrisoula D.","family":"Scopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Kottorou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athina","family":"Kominea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Peroukides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haralabos P.","family":"Kalofonos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,9,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080%2F02841860701355055"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ctrv.2008.01.003"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2FS0014-2999%2800%2900667-1"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002%2Fmus.20340"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1146%2Fannurev.genet.35.102401.091142"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1073%2Fpnas.111065098"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1085-9489.2006.00078.x"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/236049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/236049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T22:11:47Z","timestamp":1745446307000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000236049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":7,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2009,9,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000236049","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2009]]}}}